Establishment Labs Holdings Inc.

Establishment Labs® Reports Third Quarter 2026 Financial Results

Establishment Labs reported Q3 2026 revenue of $72.0 million, up 33.9% year-over-year, driven by 119% U.S. growth and a 124% increase in its minimally invasive platform. The company achieved its first-ever quarter of positive operating cash flow (~$7.7 million) and free cash flow ($5.1 million), with Adjusted EBITDA of $6.4 million, up from $1.2 million a year ago. Full-year 2026 revenue guidance was raised to more than $274 million from the prior $269-271 million range, and management expects 25% growth with positive cash flow in fiscal 2027. The company remains GAAP-unprofitable with a $10.7 million quarterly net loss and carries a $267.8 million net note payable against $75.8 million of cash.

•3d ago

Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®

Establishment Labs received FDA approval for 28 additional sizes of Motiva SmoothSilk Round and Ergonomix breast implants, including sizes as small as 105 cc. The expanded portfolio spans Mini, Demi and Full profiles and will be commercially available in the U.S. before the end of the year. Management expects the broader size range to accelerate U.S. market share gains, particularly given demand for smaller, natural-looking augmentation results.

•27d ago

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants

Establishment Labs presented new clinical and scientific data supporting its Breast Tissue Preservation initiative and Minimally Invasive Platform at the 11th World Symposium on Ergonomic Implants in Istanbul. The company announced size extensions and supporting tools for both its Mia and Preservé product lines, with CEO Peter Caldini saying the platform's success has accelerated plans to bring expanded sizes to market. Caldini cited American Society of Plastic Surgeons data showing the augmentation market has accelerated growth by 11%, which the company attributes to the impact of its innovations.

•1mo ago

Establishment Labs® Reports Second Quarter 2026 Financial Results

Establishment Labs reported Q2 revenue of $67.5 million, up 31.7% year-over-year, with U.S. sales rising 26% sequentially to $24.7 million. The company achieved a major operational milestone, turning positive on Adjusted EBITDA with income of $3.7 million compared to a loss in the prior year, while gross margin expanded to 70.6%. Management raised full-year revenue guidance to $269-$271 million and noted the business is inflecting toward high growth and free cash flow positivity.

•2mo ago

Establishment Labs® Appoints Taylor Harris to Board of Directors

Establishment Labs appointed Taylor Harris to its Board of Directors, adding over 25 years of experience in healthcare finance and executive leadership to the company. Harris previously served as CEO of Cutera and CFO of MyoKardia, guiding the latter through its $13.1 billion acquisition by Bristol Myers Squibb, and currently sits on the board of Procept BioRobotics. He brings specific expertise in the medical aesthetics industry, which aligns directly with Establishment Labs' focus on breast health and reconstruction technologies.

•4mo ago

The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real · and a Newly Public Regenerative Player Wants to Compete for It

A paid market commentary article highlights the growing trend of treating facial volume loss caused by GLP-1 weight-loss drugs, citing AbbVie's Allergan Aesthetics division as a key large-cap anchor in the space. The article notes that AbbVie's medical-affairs leadership is actively co-authoring clinical literature on treating GLP-1 aesthetic patients, validating the market opportunity alongside peers like Galderma, Establishment Labs, and InMode. While the primary focus of the advertisement is the newly public company Conexeu Sciences, the analysis frames the expanding GLP-1 aesthetics category as a significant demand driver for established industry players.

•4mo ago

Establishment Labs® Added to Membership of U.S. Small-Cap Russell 2000® Index

Establishment Labs will be added to the Russell 2000 Index, effective when the U.S. market opens on June 29, as part of the 2026 Russell indexes reconstitution. Membership is based on inclusion in the broad-market Russell 3000 Index and lasts for one year, with automatic inclusion in appropriate growth and value indexes. Approximately $12.2 trillion in assets are benchmarked against Russell US indexes, a status that often drives passive fund inflows and increases visibility among institutional investors.

•4mo ago

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Conexeu Sciences (CNXU) announced a preclinical development partnership with the Wake Forest Institute for Regenerative Medicine (WFIRM) to evaluate its proprietary B.R.E.A.S.T. 3D-printed tissue matrix. The program will leverage WFIRM’s Integrated Tissue-Organ Printing System (iTOPS) to assess durability, host tissue integration, and resorbability of the matrix, aiming to generate data for future clinical investigation. Conexeu, which commenced trading on Nasdaq on May 21, 2026, targets a 510(k) regulatory submission in early 2027 for its initial indication, positioning its CXU platform against established competitors in breast reconstruction and regenerative medicine.

•5mo ago

Establishment Labs Reports First Quarter 2026 Financial Results

Establishment Labs reported Q1 revenue of $59.9 million, up 44.7% year-over-year, with Motiva U.S. sales reaching $19.6 million. The company achieved positive Adjusted EBITDA of $1.2 million, its third consecutive profitable quarter, while gross margin expanded to 70.7%. Management raised full-year 2026 revenue guidance to $266.5 million-$268.5 million and expects the minimally invasive business to exceed $35 million.

•5mo ago

Establishment Labs® Refinances Credit Facility

Establishment Labs secured a $300 million senior secured term loan facility with Oaktree Capital Management, replacing its existing debt structure and extending the maturity profile to 2031. The facility features a two-tranche structure, with $265 million allocated to refinancing existing debt and $35 million available for strategic growth initiatives under a fixed interest rate. Management highlighted that the transaction enhances financial flexibility and expects the company to generate positive free cash flow in the second half of the year.

•6mo ago